Individual differences in preferences for and responses to four nicotine replacement products.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

The simple comparison of success rates between the products has been reported previously.

Why It Was Studied

With several different forms of nicotine replacement therapy available for smokers, it is useful to know about factors that may influence choice of form.

Who Took Part

By PubMed's age tags, the people studied were adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.

Five hundred and four smokers were invited to rank order four products (gum, patch, nasal spray and inhaler) in terms of preference and were then randomly allocated to receive one of the products for a smoking cessation attempt.

They were followed up 1 week, 4 weeks, 12 weeks and 15 weeks later.

Ratings of the products were repeated 1 week after the quit date.

Mood and physical symptoms were assessed at baseline and at each follow-up visit.

Urges to smoke were assessed at all post-quit date sessions.

What Was Measured

Abstinence was assessed by self-report with expired air carbon monoxide verification.

Topics PubMed links to this paper include Administration, Cutaneous, Administration, Inhalation, Chewing Gum, Individuality, Nicotine, Nicotinic Agonists and Smoking.

What This Means in Plain Language

The paper is a randomized and double-blind study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 12 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2001 (Psychopharmacology), a journal based in Germany.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.